Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mycophenolate Mofetil in Subclinical Interstitial Lung Disease Associated With Systemic Sclerosis
NCT05785065Phase 2Recruiting
- Sponsor
- Centre hospitalier de l’Université de Montréal
- Start
- Aug 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of mycophenolate mofetil in systemic sclerosis (SSc), interstitial lung disease (ILD), sponsored by Centre hospitalier de l’Université de Montréal. Started Aug 2024; status: recruiting.
02
Drugs
mycophenolate mofetil
03
Conditions
systemic sclerosis (SSc)interstitial lung disease (ILD)
Beyond the preview
Go deeper on NCT05785065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05785065.